Singaporean mega-investor GIC commits to Sydney office
Share
GIC, the money behind so many of Australia’s major property deals, has confirmed it is finally opening a local office in Sydney next year to source more investment opportunities.
Lim Chow Kiat, chief executive of Singapore’s sovereign wealth fund, said having people on the ground will enhance GIC’s ability to find and execute property transactions.
GIC owns 50 per cent of Chifley Tower in Sydney, making it an obvious candidate for its new Australian office next year.
Louise Kennerley
He said GIC was “very pleased” with its Australian real estate investments, which included some of the country’s best known commercial and retail buildings, and wanted more.
Annual Readers Choice Contest
cnhionline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from cnhionline.com Daily Mail and Mail on Sunday newspapers.
Глаукому лікують за допомогою лазера
gazeta.ua - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gazeta.ua Daily Mail and Mail on Sunday newspapers.
I hope it will be a major breakthrough,” said José-Alain Sahel, chair of ophthalmology at the University of Pittsburgh and director of the UPMC Eye Center. This paper is a culmination of more than 12 years of work, and I am very pleased to have contributed to this effort with Botond Roska in Basel and all my colleagues at Institut de la Vision in Paris.
Retinitis pigmentosa destroys light-sensitive cells in the retina, which normally help transmit nerve impulses through the optic nerve to the brain to form the images we see. The disease causes mutations in more than 71 different genes, making most gene therapy approaches impractical and ineffective.
Optogenetic therapy used to partially restore vision in a blind person
Shane McGlaun - May 25, 2021, 8:19am CDT
The manipulation of proteins in cells inside the body using light is called optogenetic therapy and was first developed in the early 2000s. Its development resulted in several significant discoveries about the inner working of the human brain and was actively researched in animals. Since most of the research using the technique was focused on animal trials, functional improvement using optogenetic therapy was never reported in humans.
Improvement in humans has now been reported in a new paper published by a group of scientists from the University of Pittsburgh and other institutions around the world. The study describes the first time a patient has achieved partial functional recovery from a neurodegenerative disease using optogenetic treatments. In this case, a blind patient partially recovered their vision after treatment.